Clinical Trials › NCT05285904
Active, Not Recruiting
Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study
Sponsored by Novartis Pharmaceuticals
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 107
Target enrollment
May 2022
Start date
Mar 2026
Expected completion
Interventions / Treatments
Ofatumumab
Conditions studied
Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
The app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.